Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients

Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.

Original reporting
Published Nov 22, 2026, 1:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 22, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients — source image
Decision brief

The 30-second read

$AVRBullishMed
01

Why it matters

The data show low mortality, low stroke, and strong hemodynamic performance, which could enhance the company's growth outlook.

02

Market read

First‑time release of positive trial data for a micro‑cap medical‑device firm, likely to move the stock.

03

What to watch

Regulatory approval timeline and reimbursement coverage could delay commercial impact.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Anteris Technologies Global Corp. (AVR) announced one‑year clinical results for its DurAVR transcatheter heart valve in a high‑risk aortic stenosis cohort.

Company-level read

Ticker impact

$AVRBullishHigh confidence
Context

Anteris disclosed first‑time one‑year DurAVR heart‑valve trial data showing low mortality and strong performance.

Expected impact

likely upward pressure as investors price in favorable clinical results

Evidence & confidence

First disclosure of robust one‑year data for a high‑risk patient group; no prior public release.

Market effects

May boost confidence in transcatheter valve market and related device makers.

Limited to US and European cardiovascular device investors.

Modest; primarily affects niche medical‑device segment.

Counterpoint

Trial size is small (100 patients); long‑term durability still uncertain.

Key entities

  • Anteris Technologies Global Corp.

    Developer of the DurAVR transcatheter heart valve.

  • DurAVR Transcatheter Heart Valve

    Device evaluated in the one‑year study.

Related articles

$AVRLow

Anteris Technologies Global Corp. (AVR): Results for announcement to the market Name of entity

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Results for announcement to the market Name of entity: Anteris Technologies Global Corp. (“ATGC”) ARBN: 677 960 235 Reporting period: For the quarter ended September 30, 2026 The attached Form 10-Q Quarterly Report for the quarter ended September 30, 2026 (the “Form

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.